scholarly article | Q13442814 |
P356 | DOI | 10.1177/0269881108099418 |
P698 | PubMed publication ID | 19074536 |
P50 | author | Eduard Vieta | Q20090640 |
P2093 | author name string | D Keller | |
J Miceli | |||
A D Loebel | |||
P A English | |||
T Ramey | |||
P2860 | cites work | What really matters to bipolar patients' caregivers: sources of family burden. | Q51916677 |
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics | Q55969829 | ||
Atypical antipsychotics in the treatment of mood disorders | Q57612899 | ||
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group | Q33178075 | ||
Is there a role for 5-HT1A agonists in the treatment of depression? | Q34174041 | ||
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania | Q34531273 | ||
Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies | Q34558705 | ||
Molecular targets in the treatment of anxiety | Q35001313 | ||
Treatment of acute mania--from clinical trials to recommendations for clinical practice | Q35965556 | ||
Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications | Q36550498 | ||
Mania | Q41439578 | ||
Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial | Q44385585 | ||
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania | Q44684784 | ||
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol | Q45168624 | ||
Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial | Q46596821 | ||
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia | Q46628164 | ||
Risperidone in the treatment of acute mania: double-blind, placebo-controlled study | Q46681460 | ||
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 | ||
Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial | Q46683979 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | placebo | Q269829 |
P304 | page(s) | 547-558 | |
P577 | publication date | 2008-12-12 | |
P1433 | published in | Journal of Psychopharmacology | Q6295819 |
P1476 | title | Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study | |
P478 | volume | 24 |
Q35236966 | Acute and long-term treatment of mania. |
Q37933405 | Adverse Drug Events Related to Ziprasidone: A Meta-analysis of Randomized, Placebo-Controlled Trials |
Q38884279 | Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management |
Q38003196 | Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder |
Q44142664 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. |
Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
Q38003197 | Efficacy of antimanic treatments in mixed states |
Q24601815 | Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials |
Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
Q38284625 | Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder |
Q36588607 | Evidence review and clinical guidance for the use of ziprasidone in Canada |
Q53080275 | Factors modifying drug and placebo responses in randomized trials for bipolar mania. |
Q47381585 | Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study |
Q47314501 | Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study |
Q39049252 | Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder? |
Q59336772 | Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision |
Q33529314 | Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis |
Q37960632 | Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review |
Q37908140 | Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder |
Q38413932 | Revisiting loxapine: a systematic review |
Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
Q38003199 | The clinical management of bipolar disorder complexity using a stratified model |
Q38132709 | The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study |
Q37873301 | The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder |
Q38268590 | Weight gain and antipsychotics: a drug safety review |
Q37850820 | Ziprasidone for maintenance treatment of bipolar I disorder in adults |
Q37244876 | Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study |
Q37336886 | Ziprasidone in the treatment of affective disorders: a review. |
Search more.